Skip to main content

Table 2 Summary of events and characteristics by study

From: Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis

 SUN (n = 989)SHINE (n = 561)US3 (n = 807)RISE (n = 1219)
BUD/FORM 160/4.5 μg bid (n = 494)FORM
4.5 μg bid (n = 495)
BUD/FORM 160/4.5 μg bid (n = 277)FORM
4.5 μg bid (n = 284)
BUD/FORM 160/4.5 μg bid (n = 404)FORM
4.5 μg bid (n = 403)
BUD/FORM 160/4.5 μg bid (n = 606)FORM
4.5 μg bid (n = 613)
Any CID343 (69.4)360 (72.7)173 (62.5)196 (69.0)280 (69.3)305 (75.7)468 (77.2)517 (84.3)
Subtypes of first CID
 Exacerbation alone81 (23.6)96 (26.7)47 (27.2)47 (24.0)114 (40.7)126 (41.3)61 (13.0)74 (14.3)
 FEV1 event alone120 (35.0)112 (31.1)62 (35.8)59 (30.1)90 (32.1)86 (28.2)172 (36.8)174 (33.7)
SGRQ alone116 (33.8)112 (31.1)49 (28.3)76 (38.8)61 (21.8)75 (24.6)172 (36.8)171 (33.1)
 Exacerbation + FEV13 (0.9)5 (1.4)0 (0.0)2 (1.0)6 (2.1)8 (2.6)5 (1.1)7 (1.4)
 Exacerbation + SGRQ3 (0.9)4 (1.1)4 (2.3)2 (1.0)1 (0.4)4 (1.3)6 (1.3)7 (1.4)
 FEV1 + SGRQ20 (5.8)30 (8.3)10 (5.8)10 (5.1)7 (2.5)5 (1.6)51 (10.9)79 (15.3)
 Exacerbation + FEV1 + SGRQ0 (0)1 (0.3)1 (0.6)0 (0)1 (0.4)1 (0.3)1 (0.2)5 (1.0)
Individual components
 Exacerbations152 (30.8)177 (35.8)69 (24.9)78 (27.5)169 (41.8)182 (45.2)151 (24.9)181 (29.5)
 FEV1 events196 (39.7)212 (42.8)84 (30.3)100 (35.2)135 (33.4)161 (40.0)289 (47.7)344 (56.1)
 SGRQ events188 (38.1)202 (40.8)81 (29.2)116 (40.8)143 (35.4)164 (40.7)312 (51.5)357 (58.2)
  1. Event rates in percentage of total number of patients; CID sub-events in percentage of total CID events
  2. The rows with individual components (exacerbations, FEV1 events, SGRQ events) describe events as independent variables, whereas the subtypes of first CID events describe the variable/combination occurring first within a patient. Bid, twice daily; BUD Budesonide, CID Clinically Important Deterioration, FEV1 Forced expiratory volume in 1 s, FORM Formoterol, SGRQ St George’s Respiratory Questionnaire